Inflammation may explain why women with no standard modifiable risk factors have heart attacks and strokes

(Press-News.org) Mass General Brigham researchers find that many at-risk women who are missed by traditional screening techniques have high levels of the inflammatory marker hsCRP Treating these women with statins can lower these risks by 38% New clinical syndrome of “SMuRF-Less but Inflamed” introduced  

Cardiologists have long known that up to half of all heart attacks and strokes occur among apparently healthy individuals who do not smoke and do not have high blood pressure, high cholesterol, or diabetes, the “standard modifiable risk factors” which doctors often call “SMuRFs.”  How to identify risk among the “SMuRF-Less” has been an elusive goal in preventive cardiology, particularly in women who are often under-diagnosed and under-treated. A new study by Mass General Brigham researchers that leverages data from the Women’s Health Study has found hsCRP—a marker of inflammation—can help identify women who are at risk but are missed by current screening algorithms. Results are presented at a late-breaking clinical science session at the European Society of Cardiology Congress (ESC) and simultaneously published in The European Heart Journal.

“Women who suffer from heart attacks and strokes yet have no standard modifiable risk factors are not identified by the risk equations doctors use in daily practice,” said Paul Ridker, MD, MPH, a preventive cardiologist at Mass General Brigham’s Heart and Vascular Institute. “Yet our data clearly show that apparently healthy women who are inflamed are at substantial lifetime risk. We should be identifying these women in their 40s, at a time when they can initiate preventive care, not wait for the disease to establish itself in their 70s when it is often too late to make a real difference.”

As part of the federally funded study, researchers studied 12,530 initially healthy women with no standard modifiable risk factors who had the inflammatory biomarker hsCRP measured at study entry and who were then followed over 30 years. Despite the lack of traditional risks, women who were inflamed as defined by hsCRP levels > 3 mg/L had a 77% increased lifetime risk of coronary heart disease, a 39% increased lifetime risk of stroke, and a 52% increased lifetime risk of any major cardiovascular event.

Additionally, researchers released a new analysis of randomized trial data showing that “SMuRF-Less but Inflamed” patients can reduce their risk of heart attack and stroke by 38% using statin therapy. 

“While those with inflammation should aggressively initiate lifestyle and behavioral preventive efforts, statin therapy could also play an important role in helping reduce risk among these individuals,” said Ridker.

Authorship: Mass General Brigham authors include Paul Ridker, Vinayaga Moorthy, Samia Mora, Julie Buring. Additional authors include Gemma Figtree.

Disclosures: Ridker has received institutional research grant support from multiple pharmaceutical companies and the National Heart, Lung, and Blood Institute; served as a consultant to various biomedical firms; holds minority shareholder equity in several biotech companies; and receives compensation for advisory board service. Buring serves as the Principal Investigator of the NIH-funded Women’s Health Study.

Funding: This study was funded in part by the National Heart, Lung and Blood Institute (NCT00000479).

Paper cited: Ridker P et al. “C-Reactive Protein and Cardiovascular Risk Among 12,530 Women with No Standard Modifiable Risk Factors: The “SMuRF-Less but Inflamed” Women’s Health Sub-Study” European Heart Journal DOI: 10.1093/eurheartj/ehaf658

About Mass General Brigham

Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.

 

 

 

 

 

 

 

END